Market Overview

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Share:
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of August 24th – 30th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view full article.

10. How and Why Psychedelics Created the Silicon Valley Phenomenon

Psychedelics Came About as a Result of the Counterculture Influence of LSD That Began in the Late 1960s

Legendary computer scientists and developers who built the computer industry were devotees of LSD, including the founders of current-day tech giants Microsoft Corporation (NASDAQ: MSFT) and Apple Inc. (NASDAQ: AAPL), Bill Gates and the late Steve Jobs.

READ FULL SILICON VALLEY ARTICLE

9. Champignon Brands’ CRTCE Clinic to Begin Offering Esketamine Treatment for Adults with MDD

The Company Also Provided an Update on Continuous Disclosure Review and Interim Financial Statements

Champignon Brands (OTCQB: SHRMF) announced that the company has expanded its rapid-onset treatment service to include Major Depressive Disorder (MDD). Champignon’s flagship clinic, the Canadian Rapid Treatment Centre of Excellence (CRTCE), will now offer Esketamine treatment for adults with MDD.

READ FULL CHAMPIGNON BRANDS ARTICLE

8. 2 Cannabis Stocks Producing an Actual Operating Profit

Nothing Boosts Marijuana Investors’ Confidence More Than the Ability to Make Money

Two Cannabis StocksGreen Thumb (OTCQX: GTBIF) and Village Farms (NASDAQ: VFF) are receiving a lot of attention for their ability to do just that. The former’s profitability has been soaring while the latter is just on the verge of breaking even. Let’s take a look at why their stocks are enticing opportunities.

READ FULL OPERATING PROFIT ARTICLE

7. Medical Cannabis Company Trulieve to Unveil New Milestone for its Market: THC Edibles

To Prepare for the Rollout, Trulieve Has Built a Commercial-Grade Kitchen at its Production Facility in Quincy Florida

Pending approval from the state’s health department, Florida‘s largest medical Cannabis company Trulieve (OTCQX: TCNNF) is expanding its product line with a notable introduction—THC Edibles.

READ FULL TRULIEVE ARTICLE

6. MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

MindMed is Funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab

MindMed (OTCQB: MMEDF), the leading neuro-pharmaceutical company for Psychedelic inspired medicines and the University Hospital Basel’s Liechti Lab are now combining MDMA and LSD in a groundbreaking Phase 1 clinical trial. The Phase 1 MDMA-LSD trial is scheduled to start in Q4 of this year in Basel, Switzerland.

READ FULL MINDMED ARTICLE

5. Top Marijuana Stock To Expand In Canada’s Biggest Retail Market

Canopy Growth, Which is the Biggest Pot Stock By Market Cap, Said it Would Open Both its Tweed and Tokyo Smoke Shops in the Province, With Most Appearing in Calgary

Canopy Growth (NYSE: CGC) on Friday said it would open 10 physical retail locations next week in Alberta, the first of its stores to appear in a province that already has far more pot shops than any other.

READ FULL CANOPY GROWTH ARTICLE

4. Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to Also Explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics (OTCPK: RVVTF) announced that following the U.S. Food and Drug Administration (FDA) approval to proceed with the company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19, the company has submitted its clinical trial protocol for independent Institutional Review Board (IRB) approval.

READ FULL REVIVE ARTICLE

3. Barbarians at the Gate: Institutions are Buying U.S. Cannabis Stocks

Money Managers Are Taking Positions in Cannabis Stocks Ahead of Elections

Wasatch Advisors Inc., the Utah-based asset manager, is now the second-largest holder of Cresco Labs (OTCQX: CRLBF) and an investor in Green Thumb (OTCQX: GTBIF), both Chicago-based MSOs, while Fidelity Investments is an investor in Curaleaf (OTCQX: CURLF), the Wakefield, Massachusetts-based MSO. An industry insider recently confirmed to me that, “big institutional investors are buying big slugs, quietly.”

READ FULL U.S. CANNABIS STOCKS ARTICLE

2. Psychedelic Drugs Eye Long Trip To Legalization But This U.S. IPO Won’t Wait

Psychedelic Startups, Backed By Investors Dangling Money and Stock Listings, Are Jumping in and As They Do, They’re Also Bringing Capitalism’s Competitive Drive to Substances Rooted in Cultures That Often Avoided it

On Friday, London-based Compass Pathways, which is backed by PayPal Holdings Inc (NASDAQ: PYPL) and Palantir co-founder Peter Thiel, filed for a U.S. IPO to trade on the NASDAQ under the ticker CMPS. It plans to use proceeds to research a depression therapy that uses Psilocybin, the psychoactive compound found in “Magic Mushrooms.”

READ FULL COMPASS PATHWAYS ARTICLE

1. Two of the Largest Pot Producers Are Rumored to Be Merging

Rumours of a Merger Between Two of the Largest U.S. MSOs Have Wafted for Weeks

A combination of Green Thumb (OTCQX: GTBIF) and Trulieve (OTCQX: TCNNF) would create a multi-state operator (MSO) that would rival the biggest licensed seller in the country, and the world: Curaleaf (OTCQX: CURLF).

READ FULL MEGA MERGER ARTICLE

Photo by Esteban Lopez on Unsplash

 

Related Articles (AAPL + CGC)

View Comments and Join the Discussion!

Posted-In: Apple cannabis industry Microsoft Corporation (MSFT)Earnings News Penny Stocks Markets General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com